Malaysia Nuclear Medicines market was valued at $33.68 million in 2020, and is projected to reach $70.24 million by 2028, registering a CAGR of 9.86% from 2020 to 2028.
Radiopharmaceuticals are the radioactive materials or the radioisotopes that when bound to biological molecules, are able to target specific tissues, organs, or cells within the human body. These radioactive drugs can be used for the diagnosis and increasingly, for the therapy of diseases. A radiopharmaceutical can be observed as an entity built up having radionuclide and a vehicle molecule with high affinity or binding power toward tissue or a specific function of a human organ. Furthermore, it may comprise only the radioisotope itself if it illustrates suitable biological properties.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Market players are adopting growth strategies such as product launches, mergers & acquisitions (M&As), and partnerships & collaborations to create sustainable position in the market. For instance, in March 2021, GE Healthcare unveiled StarGuide, a next-generation SPECT/CT system that uses the latest digital technologies to help clinicians improve patient outcomes in bone procedures, cardiology, neurology, oncology, and other medical specialties. The key players operating in the market are Cardinal Health, Inc., Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), GE Healthcare, Ion Beam Applications (Ion Beam Applications, SA), Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.), MERCK KGAA (Sigma Aldrich), Novartis AG (Advanced Accelerator Applications S.A.), Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH), Siemens Healthcare GmbH, and Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp)
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/11880
The Malaysia nuclear medicine/radiopharmaceuticals market is poised to grow at a significant pace, owing to the demand for non-invasive techniques, availability of effective cancer treatment, and ability to observe the functioning of the organ from outside the body. Factors that drive the use of radiopharmaceuticals include change in lifestyle, elevated levels of stress, and their ability to identify various diseases sooner than other diagnostic tests. However, factors such as supply volatility & logistical challenges, stringent regulatory norms, and competition from conventional diagnostic procedures impede the market growth. Furthermore, surge in incidence of cancer & cardiovascular aliments in Malaysia, rising demand for alpha radio immunotherapy-based targeted cancer treatment that is propelling the need for nuclear imaging techniques, and advancements in radiotracers will open new avenues in the radiopharmaceuticals market.
๐๐ฎ๐ฒ ๐๐จ๐ฐ https://www.alliedmarketresearch.com/checkout-final/82cf6331455369fa92ac09ab6c5cfda1
By modality, the Malaysia nuclear medicine market is segregated into SPECT, PET, beta emitters, alpha emitters, brachytherapy, and others. The SPECT segment is expected to witness considerable market growth during the forecast period, owing to increase in the market for medical diagnosis such as cancer, cardiology, and neurology. Furthermore, getting multiple 2-D and 3-D images that are found by performing SPECT imaging technique helps in receiving better access in visualization and is useful for the physicians.
By application, the Malaysia nuclear medicine market is segregated into oncology, cardiology, thyroid, neurology, and others. The oncology segment is expected to witness substantial market growth during the forecast period, owing to increase in advancements of radio-therapeutics which has propelled the ease in the treatment process of cancerous tumors and surge in the incidences of cancer.
By end user, the Malaysia nuclear medicine market is segregated into hospitals & diagnostics centers and research institutes. The hospitals & diagnostic centers segment is expected to witness significant market growth during the forecast period, owing to increased patient flow in the hospitals and the higher preference toward hospitals and diagnostic centers.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/11880
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- By type, the diagnostics segment was the highest contributor to the market in 2020.
- By modality, the SPECT segment is anticipated to register highest revenue shares during the forecast period.
- By application, the oncology segment is anticipated to gain highest revenue shares in the coming years.
- By end user, hospitals & diagnostic centers segment is anticipated to gain highest revenue.
๐๐ฎ๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐ฏ๐ข๐๐๐ฌ ๐๐จ๐ฎ ๐๐ง๐ฌ๐ฐ๐๐ซ ๐ญ๐จ ๐๐๐ฅ๐จ๐ฐ ๐๐๐ง๐ญ๐ข๐จ๐ง๐๐ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง:
โข Which are the driving factors responsible for the growth of market?
โข Which are the roadblock factors of this market?
โข What are the new opportunities, by which market will grow in coming years?
โข What are the trends of this market?
โข Which are main factors responsible for new product launch?
โข How big is the global & regional market in terms of revenue, sales and production?
โข How far will the market grow in forecast period in terms of revenue, sales and production?
โข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
โข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
โข Which region has more opportunities?
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com